Mebendazole is a potent inhibitor to chemoresistant T cell acute lymphoblastic leukemia cells. (2020)

Peer-Reviewed Study · Xiaolei Wang; Kaiyan Lou; Xiaodong Song et al. · June 1, 2020

Xiaolei Wang et al., 2020-06-01: Wang et al. show mebendazole kills chemoresistant T-ALL cells at nanomolar concentrations, suppresses Notch1 signalling, and slows CEM/C1 growth in murine models.

MBZ administration in murine T-ALL models also suppressed the growth of CEM/C1 cells, indicating that MBZ may be developed as a therapeutic agent for chemoresistant T-ALLs.

Xiaolei Wang et al., 2020-06-01: Wang et al. show mebendazole kills chemoresistant T-ALL cells at nanomolar concentrations, suppresses Notch1 signalling, and slows CEM/C1 growth in murine models. Study type: T-ALL cell lines (CCRF-CEM and chemoresistant CEM/C1) plus murine T-ALL models. N: not stated in the abstract. Country: China (East China University of Science and Technology, Shanghai). Dose: nanomolar concentrations in vitro; in vivo dose not stated in the abstract. Funder: not stated in the record. Declared conflicts: 'The authors have filed a patent application on the repurposing of mebendazole to T cell acute lymphoblastic leukemia (application No. 2019107596441…)' – a declared commercial interest in the finding. Comparator: the chemoresistant subline against its parent.